AZN.UK

11,964

-0.75%↓

GSK

1,480

-0.7%↓

AZN.UK

11,964

-0.75%↓

GSK

1,480

-0.7%↓

AZN.UK

11,964

-0.75%↓

GSK

1,480

-0.7%↓

AZN.UK

11,964

-0.75%↓

GSK

1,480

-0.7%↓

AZN.UK

11,964

-0.75%↓

GSK

1,480

-0.7%↓

Search

Haleon PLC

Gesloten

SectorGezondheidszorg

366.1 -0.08

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

365.3

Max

369.3

Belangrijke statistieken

By Trading Economics

Inkomsten

-254M

231M

Verkoop

-21M

2.8B

K/W

Sectorgemiddelde

21.141

35.473

Dividendrendement

1.89

Winstmarge

8.373

Werknemers

24,561

EBITDA

-317M

399M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+20.89% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.89%

2.38%

Volgende dividenddatum

18 sep 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.8B

32B

Vorige openingsprijs

366.18

Vorige sluitingsprijs

366.1

Nieuwssentiment

By Acuity

17%

83%

29 / 372 Rangschikking in Healthcare

Haleon PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

31 jul 2025, 08:02 UTC

Winsten
Belangrijke Marktbewegers

Haleon Shares Fall on Cut to Organic Revenue Guidance

31 jul 2025, 07:03 UTC

Winsten

Haleon Raises 2025 Profit Guidance, Cuts Revenue Growth Targets

15 apr 2025, 09:37 UTC

Acquisities, Fusies, Overnames

Haleon Acquires Chinese JV in $264 Million Deal

31 jul 2025, 06:14 UTC

Winsten

Analysts Saw Haleon 1H Adjusted PBT at GBP1.10B

31 jul 2025, 06:14 UTC

Winsten

Haleon 1H Adjusted PBT GBP1.11B

31 jul 2025, 06:12 UTC

Winsten

Haleon Declares 1H Dividend of 2.2 Pence

31 jul 2025, 06:11 UTC

Winsten

Haleon: Targets High-single Digit Adjusted Operating Profit Growth from 2026

31 jul 2025, 06:10 UTC

Winsten

Haleon: From 2026 Targets 4%-6% Annual Organic Revenue Growth

31 jul 2025, 06:09 UTC

Winsten

Haleon: Targets High-Single Digit Organic Operating Profit Growth in 2025

31 jul 2025, 06:08 UTC

Winsten

Haleon: Lowers Guidance to 2025 Organic Revenue at Around 3.5%

31 jul 2025, 06:05 UTC

Winsten

Haleon 1H Free Cash Flow GBP734M

31 jul 2025, 06:05 UTC

Winsten

Haleon 1H Adjusted Operating Profit Margin 22.7%

31 jul 2025, 06:05 UTC

Winsten

Haleon 1H Adjusted Operating Profit GBP1.24B

31 jul 2025, 06:02 UTC

Winsten

Analysts Saw Haleon 1H Rev GBP5.50B

31 jul 2025, 06:02 UTC

Winsten

Haleon 1H Rev GBP5.48B

27 jun 2025, 09:05 UTC

Acquisities, Fusies, Overnames

Haleon: TSKF Is Now a Wholly Owned Unit of Haleon

27 jun 2025, 09:05 UTC

Acquisities, Fusies, Overnames

Haleon: Acquired Remaining Stake for GBP0.2 Billion

27 jun 2025, 09:03 UTC

Acquisities, Fusies, Overnames

Haleon: Bought Remaining 12% Equity Interest in Tianjin TSKF Pharmaceutical

27 jun 2025, 09:01 UTC

Acquisities, Fusies, Overnames

Haleon Completed Acquisition of Remaining 12% in China JV

30 mei 2025, 13:47 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Consumer Health Sector Has Room for More Dealmaking -- Market Talk

30 apr 2025, 08:33 UTC

Marktinformatie
Winsten

Haleon's Vitamins & Supplements Business Weakness in Focus Among Results -- Market Talk

30 apr 2025, 06:09 UTC

Winsten

Haleon Expects Macroeconomic Environment to Remain Challenging, Uncertain

30 apr 2025, 06:09 UTC

Winsten

Haleon Continues to Deliver Against Capital Allocation Priorities

30 apr 2025, 06:08 UTC

Winsten

Analysts Saw Haleon 1Q Organic Revenue Growth at 5.1%

30 apr 2025, 06:03 UTC

Winsten

Haleon Sees 2025 Adjusted Operating Profit Growth Ahead of Revenue Growth

30 apr 2025, 06:03 UTC

Winsten

Haleon Sees 2025 Organic Revenue Growth of 4%-6%

30 apr 2025, 06:03 UTC

Winsten

Haleon Backs 2025 View

30 apr 2025, 06:03 UTC

Winsten

Haleon 1Q Rev GBP2.85B

30 apr 2025, 06:01 UTC

Winsten

Haleon 1Q Organic Revenue Growth up 3.5%

29 apr 2025, 19:47 UTC

Winsten

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

Peer Vergelijking

Prijswijziging

Haleon PLC Prognose

Koersdoel

By TipRanks

20.89% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 442.22Ā GBXĀ  20.89%

Hoogste 500Ā GBX

Laagste 370Ā GBX

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Haleon PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

7

Buy

2

Hold

1

Sell

Sentiment

By Acuity

29 / 372 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Haleon PLC

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.